Record attendance at BIO-Europe


Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event. Svenja Schulze, the Innovation Minister of Germany’s federal state North Rhine-Westphalia (NRW) opened the meeting on October 31 at the fairgrounds in Düsseldorf. „BIO-Europe creates new opportunities – for the participating companies and therefore for the cluster in NRW,“ said the politician. Biotechnology can provide solutions for tomorrow’s problems: „Biotechnology is important per se“, said Schulze. Bernward Garthoff, manager of the NRW biotech cluster BIO.NRW, added: „BIO-Europe is a landmark event on the calendars of business development executives from North Rhine- Westphalia. It is a perfect platform to raise our international profile and forge stronger links with the innovators from around the world.“
The main purpose of the event is to create new partnerships. Participants can schedule meetings online in advance of the conference, while on the spot, deals are negotiated in over 1,000 partnering booths. This year, more than 15,000 meetings were held during the three day conference. In addition to the partnering opportunities, BIO- Europe offered a vast number of discussion panels and forums at the fair, where experienced industry representatives analyse the latest trends. This included this year, again the field of personalised medicine: Even ten years after the completion of the Human Genome Project–it seems to remain at an early stage. In the eyes of Peer Schatz, CEO of Qiagen, personalised medicine, however, involves more than just the development of tailor-made drugs: “Data management is key“ said Schatz. “More information leads to better decisions and a better outcome”, he added. In the future, the results of different diagnostic methods, such as molecular biology or imaging techniques will be combined with personal sequence data. „The modern doctor will have to manage complex mathematical algorithms,“ said Schatz.

Germany, FranceGermany


Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...



Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...



Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...



Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...



While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...



Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...



Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...



Leverkusen - Bayer Pharma has a lucky streak. The pharma division of the German chemical giant announced positive Phase III results from regorafenib in colorectal cancer. “We are extremely encouraged by the result of this...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Stock list

All quotes


  • ZEALAND PHARMA (DK)131.00 DKK10.08%
  • DIAMYD MEDICAL -B- (S)4.69 SEK8.56%
  • IPSEN (F)59.44 EUR6.68%


  • MOLOGEN (D)2.05 EUR-10.87%
  • PHARMING (NL)0.22 EUR-8.33%
  • VALNEVA (F)2.40 EUR-4.38%


  • THERAMETRICS (CH)0.05 CHF66.7%
  • PROTHENA PLC (IE)55.41 USD50.8%
  • VERNALIS (UK)44.50 GBP35.9%


  • MOLOGEN (D)2.05 EUR-30.5%
  • SANTHERA (CH)55.00 CHF-26.8%
  • NICOX (F)10.49 EUR-14.3%


  • KARO BIO (S)31.20 SEK1874.7%
  • NICOX (F)10.49 EUR455.0%
  • SAREUM HOLDINGS (UK)0.77 GBP234.8%


  • BB BIOTECH (D)44.84 EUR-84.7%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 28.07.2016


All Events